Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 7682 results

  1. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development [GID-TA10024] Expected publication date: 28 June 2017

    Technology appraisal guidance
    In development

  2. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development [GID-TA10606] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions

    Awaiting development [GID-MT602] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  4. The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound

    Awaiting development [GID-MT603] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  5. Ondansetron for treating alcohol-use disorder TS ID 11884

    Awaiting development [GID-TA11375] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888

    Awaiting development [GID-TA11377] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-NG10404] Expected publication date: TBC

    NICE guideline
    In development

  8. Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

    In development [GID-TA10497] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development [GID-HTE10011] Expected publication date: TBC

    Health technology evaluations
    In development

  10. Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over TS ID 11891

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910

    Awaiting development [GID-TA11403] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development [GID-TA11154] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over TS ID 11892

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years TS ID 11887

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905

    Awaiting development [GID-TA11414] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development